Vicore Pharma Holding AB financials
Vicore Pharma Holding AB
549300KTNBPTZLF01130 | Line item | 2023 | 2022 |
|---|---|---|
| Income statement | ||
| Revenue | SEK 0 | SEK 0 |
| Gross profit | SEK 0 | SEK 0 |
| Administrative expenses | SEK 36.9M | SEK 28.4M |
| Operating profit (EBIT) | -SEK 321.5M | -SEK 290.7M |
| Net finance income / (cost) | SEK 10.2M | SEK 1.9M |
| Finance costs | SEK 358.0K | SEK 476.0K |
| Profit before tax | -SEK 311.3M | -SEK 288.8M |
| Income tax expense | -SEK 384.0K | -SEK 384.0K |
| Profit for the year | -SEK 310.9M | -SEK 288.4M |
| — attributable to owners | -SEK 310.9M | -SEK 288.4M |
| Total comprehensive income | -SEK 311.6M | -SEK 288.4M |
| Per share | ||
| Basic EPS | SEK -3.22 | SEK -3.99 |
| Diluted EPS | SEK -3.22 | SEK -3.99 |
| Cash flow statement | ||
| Net cash from operating activities | -SEK 249.6M | -SEK 299.9M |
| Net cash from investing activities | -SEK 144.5M | SEK 74.0M |
| Purchase of intangibles | SEK 0 | SEK 3.0M |
| Net cash from financing activities | SEK 470.9M | SEK 187.0M |
| Lease liability payments | SEK 63.0K | SEK 252.0K |
| Net change in cash | SEK 76.8M | -SEK 38.9M |
| Balance sheet | ||
| Total assets | SEK 497.8M | SEK 338.0M |
| Non-current assets | SEK 2.2M | SEK 68.2M |
| Property, plant & equipment | SEK 25.0K | SEK 54.0K |
| Right-of-use assets | SEK 0 | SEK 63.0K |
| Current assets | SEK 495.6M | SEK 269.8M |
| Cash & equivalents | SEK 333.6M | SEK 256.8M |
| Total equity | SEK 455.4M | SEK 289.1M |
| Non-current liabilities | SEK 1.5M | SEK 2.5M |
| Current liabilities | SEK 41.0M | SEK 46.4M |
| Lease liabilities (current) | SEK 0 | SEK 65.0K |
| Deferred tax liabilities | SEK 593.0K | SEK 905.0K |
| Derived metrics | ||
| Return on equity | -68.3% | -99.8% |
| Cash conversion ratio | 0.80× | 1.04× |
| Other reported items | ||
| Additional Paidin Capital | SEK 1.67B | SEK 1.21B |
| Adjustments For Decrease Increase In Trade and Other Receivables | -SEK 4.3M | -SEK 1.6M |
| Adjustments For Increase Decrease In Trade and Other Payables | -SEK 6.4M | -SEK 19.3M |
| Adjustments To Reconcile Profit Loss Other Than Changes In Working Capital | SEK 72.1M | SEK 10.6M |
| Cash Flows From Used In Operations Before Changes In Working Capital | -SEK 238.9M | -SEK 279.0M |
| Comprehensive Income Attributable To Owners of Parent | -SEK 311.6M | -SEK 288.4M |
| Copyrights Patents and Other Industrial Property Rights Service and Operating Rights | SEK 2.2M | SEK 68.1M |
| Current Accruals and Current Deferred Income Including Current Contract Liabilities | SEK 14.6M | SEK 18.2M |
| Current Investments | SEK 149.1M | SEK 4.9M |
| Current Prepayments and Current Accrued Income Including Current Contract Assets | SEK 9.7M | SEK 5.9M |
| Current Tax Liabilities Current | SEK 1.1M | SEK 760.0K |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | SEK 0 | SEK 1.5M |
| Equity and Liabilities | SEK 497.8M | SEK 338.0M |
| Finance Income | SEK 10.5M | SEK 2.4M |
| Increase Decrease Through Exercise of Options | SEK 7.0M | SEK 3.9M |
| Increase Decrease Through Transactions With Owners | SEK 477.9M | SEK 194.2M |
| Interest Paid Classified As Operating Activities | SEK 2.0K | SEK 8.0K |
| Interest Received Classified As Operating Activities | SEK 10.4M | SEK 1.2M |
| Issue of Equity | SEK 500.4M | SEK 203.0M |
| Issued Capital | SEK 55.9M | SEK 40.9M |
| Liabilities | SEK 42.4M | SEK 48.9M |
| Noncurrent Investments Other Than Investments Accounted For Using Equity Method | SEK 0 | SEK 0 |
| Other Comprehensive Income | -SEK 668.0K | SEK 0 |
| Other Current Liabilities | SEK 5.1M | SEK 3.8M |
| Other Current Receivables | SEK 3.1M | SEK 2.2M |
| Other Longterm Provisions | SEK 898.0K | SEK 1.6M |
| Other Operating Income Expense | -SEK 617.0K | -SEK 3.2M |
| Other Shortterm Provisions | SEK 2.2M | SEK 127.0K |
| Payments For Share Issue Costs | SEK 29.5M | SEK 12.7M |
| Proceeds From Issuing Shares | SEK 500.4M | SEK 200.0M |
| Proceeds From Sales Or Maturity of Financial Instruments Classified As Investing Activities | SEK 54.6M | SEK 77.0M |
| Purchase of Financial Instruments Classified As Investing Activities | SEK 199.0M | SEK 0 |
| Research and Development Expense | SEK 276.3M | SEK 250.0M |
| Retained Earnings | -SEK 1.27B | -SEK 962.7M |
| Sales and Marketing Expense | SEK 7.7M | SEK 9.1M |
| Share Issue Related Cost | SEK 29.5M | SEK 12.7M |
| Trade and Other Current Payables To Trade Suppliers | SEK 17.9M | SEK 23.5M |
Every line item above is a fact tagged in Vicore Pharma Holding AB's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (SEK), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.